The drug hydroxychloroquine, which is sold under the name Plagenil, was approved in 1955, now it is included in the list of vital and important drugs. During laboratory experiments, he was effective in the fight against coronavirus, Forbes reports.
To the topic Favipiravir against coronavirus: why there are doubts about the effectiveness of the drug
Plaquenil Treatment in Ukraine
Ukraine received a batch of Plaquenil drugs, which several countries have recognized effective in the treatment of COVID-19. The drugs have already been redistributed and sent to the region.
The newly elected head of the Ministry of Health Maxim Stepanov said that the drug has an active substance that is effective against coronavirus. Therefore, the Ministry of Health decided to agree additionally with a number of pharmaceutical companies for the supply of drugs that contain the same active substance as Plaquenil.
Previously, the price of Plaquenil in Ukraine was about 500 hryvnias per pack, but then it increased significantly.
Hydroxychloroquine and chloroquine – these drugs are supplied under the name Plaquenil. Chloroquine is used to treat malaria, and hydroxychloroquine is used to treat rheumatoid arthritis or systemic lupus erythematosus.
Important! According to the CDC, there are no data on the results of clinical trials of hydroxychloroquine for the treatment of COVID-19 to include it in clinical guidelines.
Actual: Suprun criticized the protocol for the treatment of coronavirus in Ukraine
Why in the US consider Plaquenil effective
On March 19, Donald Trump announced that Plaquenil would be available as a prescription in the United States. He noted that hydroxychloroquine showed “encouraging results,” but he understood that treating coronavirus with this drug requires further research.
Plaquenil (hydroxychloroquine) – what is this drug? This is an antimalarial drug that belongs to the group of immunosuppressants. It reduces the activity of the immune system.
Plaquenil is used to treat arthritis of varying severity, malaria, with skin diseases and lupus.
On March 9, a study appeared in the journal Clinical Infectious Diseases, which stated that the drug has good potential for combating coronavirus.
The laboratory study involved 36 patients. 20 patients is an experimental group where 600 mg of Plaquenil was administered daily to volunteers. But the remaining 16 patients are the control group, which was treated according to the protocol.
According to the study, on the third day, 50% of participants who were treated only with Plaquenil received a negative result for coronavirus. But on the sixth day, 70% got a negative result.
6 out of 20 patients were treated with Plaquenil in combination with the antibiotic azithromycin. Interestingly, they recovered even faster. Already on the third day, 83% of the participants received a negative result on coronavirus, and on the sixth day all 100% recovered.
Meanwhile, patients from the control group were sick longer. On the third day of the disease, only 6.3% of the participants recovered, and on the sixth – 12.5%. Interestingly, the participants in the control group were significantly younger than those who agreed to experimental treatment. The average age of the control group was 37 years, and in the experimental group 51 years.
It looks like Tocilizumab against coronavirus: doctors have announced the effectiveness of the drug
Plaquenil is wary in France
These results prompted the French Minister of Health to conduct an extended trial. Doctors agree that before recommending such treatment to the community, efficacy needs to be proven with much more research.
Also, experts noted that the use of long-approved drugs has advantages, because all the side effects have been known for a long time.
Coronavirus Mortality Data / Channel 24 Infographics
For more news regarding treatment, medicine, nutrition, a healthy lifestyle, and more, read the Health section.